• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485).
  

DOI=10.1016/B978-0-12-333530-2.50007-1
Carey T.E.
Head and neck tumor cell lines.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York; USA (1994)

PubMed=8725545; DOI=10.3109/00016489609137854
Pekkola-Heino K., Servomaa K., Kiuru A., Grenman R.
Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma.
Acta Oto-Laryngol. 116:341-344(1996)

PubMed=8782485; DOI=10.1046/j.1365-2184.1996.01009.x
Servomaa K., Kiuru A., Grenman R., Pekkola-Heino K., Pulkkinen J.O., Rytomaa T.
p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines.
Cell Prolif. 29:219-230(1996)

PubMed=9187133
Soukka T., Salmi M., Joensuu H., Hakkinen L., Sointu P., Koulu L., Kalimo K., Klemi P., Grenman R., Jalkanen S.T.
Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells.
Cancer Res. 57:2281-2289(1997)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174
Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A., Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D., Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M., Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R., Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J., McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G., Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
JCI Insight 3:e122204.1-e122204.19(2018)

DOI=10.1158/1538-7445.AM2020-507
Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J., Koritzinsky M., Wouters B.G.
Repurposing of FDA approved drugs for treatment of metastatic HNSCC.
Cancer Res. 80 Suppl. 16:507-507(2020)